Peptide harm reduction: difference between revisions
Diff·revision 5 → 6·09:49, 2 Jan 2025
Difference between revision 5 and revision 6 of Peptide harm reduction. 3 lines changed; the page grew by 452 bytes.
| Revision 5 — 06:46, 23 Dec 2024 OffLabelOdile (talk) clarify that coverage varies by plan and give the source for the example 2,300 bytes +244 | Revision 6 — 09:49, 2 Jan 2025 FlowTrialFraser (talk) rm the advice on how to obtain coverage 2,752 bytes +452 | ||
|---|---|---|---|
| 10 | The uncertainties are specific and documented elsewhere on this wiki: identity, which a purity figure does not establish; content, which determines how much active substance a vial holds; sterility, which a research-chemical powder does not have; and provenance, which determines whether any document attaches to the material at all.{{r|usp1503}} | 10 | The uncertainties are specific and documented elsewhere on this wiki: identity, which a purity figure does not establish; content, which determines how much active substance a vial holds; sterility, which a research-chemical powder does not have; and provenance, which determines whether any document attaches to the material at all.{{r|usp1503}} |
| 11 | 11 | ||
| + | 12 | This wiki's contribution to harm reduction is documentary: explaining what a determination establishes and what it does not, so that a reader can tell an informative document from an uninformative one. It does not advise on use, and research-use compounds are not approved for human administration.{{r|reports}} | |
| + | 13 | ||
| 12 | == What the uncertainties are == | 14 | == What the uncertainties are == |
| 13 | | Uncertainty | Resolved by | Commonly reported? | | 15 | | Uncertainty | Resolved by | Commonly reported? | |
| ⋮ | ⋮ | ||
| 29 | <ref name="marlatt1996">Marlatt GA. "Harm reduction: come as you are." ''Addictive Behaviors'' 21(6):779–788 (1996). PMID 8904943.</ref> | 31 | <ref name="marlatt1996">Marlatt GA. "Harm reduction: come as you are." ''Addictive Behaviors'' 21(6):779–788 (1996). PMID 8904943.</ref> |
| 30 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 32 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 33 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 31 | 34 | ||
| 32 | {{DEFAULTSORT:Peptide harm reduction}} | 35 | {{DEFAULTSORT:Peptide harm reduction}} |